Immunosuppression and Oxygenase enzyme activity in sepsis

• Research type

  Research Study

• Full title

  Heme oxygenase activity in sepsis and assessment of lymphocyte phenotypes

• IRAS ID

  211694

• Contact name

  Manu Shankar-Hari

• Contact email

  manu.shankar-hari@gstt.nhs.uk

• Sponsor organisation

  Guy's and St Thomas' NHS Foundation Trust

• Duration of Study in the UK

  2 years, 0 months, 0 days

• Research summary

  Infections stimulate defence mechanisms in the human body and leads to acute illness described as sepsis. More than a quarter of adult intensive care unit (ICU) admissions in the UK have sepsis with acute impairment of organ function e.g. of lungs, kidneys or heart. Nearly half of these patients die prior to leaving hospital. Furthermore, a proportion of those who survive may suffer severe long­term functional and psychological disability requiring support for activities of daily living. Thus the personal and financial cost to patients and society from severe sepsis is immense.
  Worryingly, rates of sepsis are increasing across the world. Newer promising treatments for sepsis identified in the last decade have not been uniformly successful. Thus identifying new treatments or optimal use of existing treatments to improve outcome is a patient necessity; clinical, research and societal priority.
  The study aims to address key knowledge gaps identified in the literature on reasons for immunosuppression in this patient population.

• REC name

  HSC REC A

• REC reference

  16/NI/0179

• Date of REC Opinion

  15 Aug 2016

• REC opinion

  Favourable Opinion